Dr. Paul E. Zorsky, MD, MS

Expert Publications

• Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells.
• Use of CD34+ cell fraction as a measure of hematopoietic stem cells in bone marrow and peripheral blood: comparison with the CFU-GM assay.
• Salvage and transfusion of autologous red blood cells from bone marrow harvest.
• Letter: Preliminary crystallographic data for Escherichia coli beta-lactamase.
• High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
• Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
• Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients.
• Optimizing high-dose therapy using pharmacokinetic principles.
• Fine needle aspiration as a means to cost-effective health care.
• Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.

Media Releases

Get to know Oncologist Dr. Paul E. Zorsky, who serves patients in Amarillo, Texas.

Having worked in the oncology and hematology fields for more than 30 years, Dr. Zorksy sees patients at Harrington Cancer Center in Amarillo, Texas. 

Harrington Cancer Center is dedicated to providing the most advanced cancer care and treatment in the Texas Panhandle region. The team of professionals working there provides a unique, team approach to providing consultation, evaluation, diagnosis, and comprehensive treatment.

Originally from Connecticut, Dr. Zorsky received his Bachelor of Science (BS) degree in Chemical Engineering and his Master of Science (MS) degree in Biochemistry from the University of Connecticut. He then went on to obtain his Doctor of Medicine (MD) degree from the University of Connecticut School of Medicine. Wanting to further his training, he completed his residency in internal medicine and his fellowship in oncology and hematology at The George Washington University Medical Center in Washington, D.C. 

Following his education, the doctor became board-certified in internal medicine, medical oncology, and hematology by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world. 

Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A medical professional who practices oncology is an oncologist. An oncologist is a doctor who treats cancer and provides medical care for a person diagnosed with cancer. They lead a cancer treatment team of various healthcare professionals, treat patients with radiation therapy, coordinate treatment plans and prescribe various types of treatment, including chemotherapy and immunotherapy, as well as assist patients with pain management.

In honor of his clinical excellence, Dr. Zorsky is the recipient of Compassionate Doctor Recognition (2014, 2018), Patients’ Choice Award (2014, 2015, 2018), and Top 10 Doctor – City (2014).

Recommended Articles

• How is Multiple Myeloma Diagnosed?

  Various tests are conducted for the diagnosis of multiple myeloma since one result of a laboratory test cannot diagnose it alone. A number of factors like the history, complete body check-up, diagnostic test reports and symptoms of the patient are taken into consideration to get a proper diagnosis...

• Roles of the National Coalition for Cancer Survivorship

  The National Coalition for Cancer Survivorship (NCCS) is a nonprofit, cancer advocacy organization that is located just outside of Washington D.C. To date, it is the oldest survivor-led cancer advocacy organization in the United States.The NCCS represents millions of Americans who share a common...

• New Diagnostic Tool Approved for Lymphoma

  A new diagnostic tool has been approved by the U.S. Food and Drug Administration (FDA) to help researchers identify leukemia and lymphoma cells by using a technique known as flow cytometry. A flow cytometry test for non-Hodgkin’s lymphoma (NHL) can help determine whether normal or abnormal DNA is...

• 9/11 Ground Zero Worker's Lymphoma Improves with Clinical Trial

  When the terrorist attacks occurred in New York on September 11th, 2001, Bart Zagami, a 61-year-old New York State Supreme Court officer, was in his office just a few blocks away from the World Trade Center in lower Manhattan. Days after the 9/11 terrorist attacks, Zagami spent his time at Ground...

• Life Lessons After Multiple Misdiagnoses of Lymphoma

  28-year-old Jessica DeCristofaro had been coughing persistently and she was told by her doctor that it was a result of allergies. She even took medication for her supposed allergies over the course of two years. When the medication failed to improve her persistent cough, another doctor diagnosed her...

• John Quinones Teams Up With Survivors For Leukemia and Lymphoma Society

  Many cancer patients suffer in silence, with the public being largely unaware of the different types of cancer and how they affect patients. Most people obviously know that cancer is well, a bad thing, but there is a lot of nuance and important information that is lost on the common citizen. Most...